Compare OVID & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | BBNX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 493.1M |
| IPO Year | 2017 | N/A |
| Metric | OVID | BBNX |
|---|---|---|
| Price | $2.64 | $16.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $4.60 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-13-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | $19.34 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.52 | $8.80 |
| 52 Week High | $3.11 | $32.71 |
| Indicator | OVID | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 42.57 |
| Support Level | $2.56 | $12.87 |
| Resistance Level | $2.77 | $15.26 |
| Average True Range (ATR) | 0.15 | 1.19 |
| MACD | 0.03 | -0.36 |
| Stochastic Oscillator | 92.78 | 25.23 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.